ASCO GU 2024 Expert Analysis

CE / CME

Expert Analysis of Key Studies at the 2024 ASCO Genitourinary Cancers Symposium

Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits

Nurses: 1.50 Nursing contact hours

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Pharmacists: 1.50 contact hours (0.15 CEUs)

Released: March 25, 2024

Expiration: March 24, 2025

Terence Friedlander
Terence Friedlander, MD
Rana R. McKay
Rana R. McKay, MD

Activity

Progress
1 2
Course Completed

Introduction

In this module, Terence Friedlander, MD, and Rana McKay, MD, provide an overview and expert analysis of key studies presented at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, including novel agents for treatment of genitourinary cancers and best practices for integrating these novel therapies into your clinical practice.  

The key points discussed in this module are illustrated with thumbnails from accompanying downloadable PowerPoint slidesets that can be found here or downloaded by clicking any of the slide thumbnails in this module.

CCO plans to measure the educational impact of this activity. Several questions will be asked twice: once at the beginning of the activity, and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

For those providing patient care, how many patients with genitourinary cancers do you provide care for in a typical month?

Based on data presented at ASCO GU 2024 from the phase II BRCAAway trial that compared olaparib vs olaparib plus abiraterone/prednisone vs abiraterone/prednisone, which of the following treatment approaches would you recommend to optimize outcomes for a patient with newly diagnosed metastatic castration-resistant prostate cancer (mCRPC), no prior therapy beyond androgen deprivation therapy (ADT), and a BRCA2 mutation?

Which of the following accurately describes the PFS and overall survival (OS) results from the subgroup analysis of the phase III EV-302/KEYNOTE-A39 that compared first-line enfortumab vedotin (EV) plus pembrolizumab vs chemotherapy in patients with locally advanced/metastatic urothelial carcinoma?

When discussing data reported at ASCO GU 2024 from the PemCab trial with your colleague, which of the following would you indicate regarding the safety profile of the combination of pembrolizumab plus cabozantinib in patients with previously untreated advanced bladder cancer?

When discussing treatment options erdafitinib and EV with your patient who has previously treated FGFR3-altered bladder cancer, which of the following would you indicate regarding the median OS outcomes for EV followed by erdafitinib vs erdafitinib followed by EV from the retrospective analysis of the UNITE database presented at ASCO GU 2024?